Nanosonics Limited · ASX:NAN
Nanosonics — H1 FY2016 Earnings Presentation
19 slides from Nanosonics's earnings presentation, February 2016
Slide 1: Nanosonics Limited 2016 Half Year Results
Nanosonics Limited 2016 Half Year Results Investor Presentation Michael Kavanagh CEO & President McGregor Grant Chief Financial Officer
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Corporate Mission
Corporate Mission We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. Johns Hopkins Photo Credit: American Nur
Slide 4: Corporate objectives
Corporate objectives Customer Experience Establish our offerings as new standards of care globally and provide customers a convenient, seamless and consistent experience with both product and brand. Product Innovation Operational Excellence People Engagement Create and bring to market a Develop an a
Slide 5: Company Overview
Company Overview • Proprietary automated technology for low Key Corporate Data temperature, high level disinfection Share price* $1.87 • First product, trophon® EPR, for high level Shares on issue* 283.51 million disinfection of ultrasound probes Market capitalisation* $530 million • Approved for sa
Slide 6: 2016 H1 Highlights
2016 H1 Highlights • First full half under new North American direct operations delivers record sales of $15.5 million. • Installed base in North America increased by over 1,700 units in half with total installed base now in excess of 6,700 units. • Publication of HPV study demonstrating trophon as
Slide 7: 2016 H1 Financial Results
2016 H1 Financial Results Sales $21.5 $22.2 • Record sales of $15.6 million under $ million first full half operating with new North H1 H2 $14.9 $7.9 $15.6 American business model. $11.8 $12.3 • No trophon unit sales to GE $10.5 Healthcare in North America in period $7.2 $14.3 $15.6 (note: GEHC reco
Slide 8: 2016 Financial Results
2016 Financial Results FY16 FY15 FY14 • Sales up 8.6% to $15.6 million – In line with plan as North American direct sales fully operational $ million H1 H1 H2 FY15 H1 H2 FY14 • Gross Profit up $3.4 million to $12.6 million Sales Revenue 15.6 14.3 7.9 22.2 9.7 11.8 21.5 • GP% 81% vs pcp 64% mainly du
Slide 9: Excellent growth momentum under new North American business model
Excellent growth momentum under new North American business model Quarterly Sales • Steady growth over the past $ million four quarters following the announcement of North American direct operations – FY15 Q3 – Announced new business model $9.1 – FY15 Q3 / Q4 – Established $8.3 North American operat
Slide 10: Trophon becoming standard of care in North America
Trophon becoming standard of care in North America • Installed base increased by over 1,700 units in H1 FY16 • There are now more than 6,700 trophon EPR systems in operation across 2,000 facilities including 44 of top 50 hospitals • Estimated market opportunity in excess of 40,000 systems 6,700 Nort
Slide 11: Regional Highlights
Regional Highlights Europe UK awaiting guidelines from England and Scotland (expected Q4). Pipeline growing strongly in anticipation of guidelines. 25 NHS trusts (46 hospitals) already adopted trophon. 9 of the 25 have followed up initial purchase with additional units Welsh guidelines release
Slide 12: Fundamentals for adoption continue to strengthen
Fundamentals for adoption continue to strengthen. The Hospital-Acquired Condition (HAC) Reduction Program1 The Joint Commission Non compliance with infection control standards associated with medical equipment & devices is one of the top 5 findings by The Joint Commission2 CDC Health Advisory - publ
Slide 13: HPV – A real risk of cross contamination through ultrasound examination
HPV – A real risk of cross contamination through ultrasound examination - For patients AND staff • “a considerable number of ultrasound probes contaminated with human and HR-HPV DNA, despite LLD disinfection and probe cover”1 • A substantial 1 persistence of microorganisms observed on disinfected pr
Slide 14: trophon EPR first and only system to kill HPV
trophon EPR first and only system to kill HPV • 2014 study showed disinfectants commonly used on ultrasound probes not effective against human papillomavirus (HPV)1 • Second study demonstrated that trophon EPR is the first and only system proven to kill high-risk, cancer-causing strains of HPV2 1. M
Slide 15: Why is trophon being adopted as Standard of Care?
Why is trophon® being adopted as Standard of Care? Reduces the risk of ultrasound HAIs Extensive clinical validation Only system proven to kill HPV Simpler to use with consistent results Creates a safer environment for patients & staff No exposure to harmful chemicals or fumes Easy to HLD
Slide 16: Compatible with more than 950 ultrasound transducer models
Compatible with more than 950 ultrasound transducer models • Covers all world’s leading manufacturers • Includes both intracavitary and surface probes 16
Slide 17: R&D investment
R&D investment • $3.3 million in half invested in R&D activities across mechanical, electrical and software engineering, microbiology and chemistry • Active programs underway on: – Next generation trophon – New decontamination devices – New disinfectant chemistries 17
Slide 18: Business Outlook – Positive momentum continues
Business Outlook – Positive momentum continues • Direct North American sales operations in place and delivering encouraging results. • Becoming standard of care in North America with >6700 units installed. • New supporting guidelines expected in UK, France and Japan • Expansion into new territories
Slide 19: narosonics
narosonics (LM ire n. For Life.